

WHAT IS CLAIMED:

1. An isolated hepatitis C virus (HCV) asialoglycoprotein selected from the group consisting of E1 and E2.

2. The asialoglycoprotein of claim 1, wherein said asialoglycoprotein is E1.

3. The asialoglycoprotein of claim 1, wherein said asialoglycoprotein is E2.

4. The asialoglycoprotein of claim 2, wherein said E1 asialoglycoprotein is recombinant E1.

5. The asialoglycoprotein of claim 2, wherein said E1 asialoglycoprotein is recombinant E2.

6. A method for producing hepatitis C virus (HCV) asialoglycoproteins suitable for use in a vaccine or immunoassay, which method comprises:

growing a lower eukaryote transformed with a structural gene encoding an HCV asialoglycoprotein selected from the group consisting of E1 and E2 in a suitable culture medium;

causing expression of said structural gene; and

recovering said HCV asialoglycoprotein from said cell culture.

7. The method of claim 6, wherein said lower eukaryote is yeast.

8. The method of claim 7, wherein said yeast is *Saccharomyces*.

9. The method of claim 7, wherein said yeast is phenotypically pmr1.

5 10. The method of claim 6, wherein said HCV asialoglycoprotein structural gene further comprises a polynucleotide encoding a secretion leader functional in said lower eukaryote.

10 11. The method of claim 10, wherein said secretion leader comprises the α -factor secretion leader.

15 12. A method for producing hepatitis C virus (HCV) asialoglycoproteins suitable for use in a vaccine or immunoassay, which method comprises:

growing a mammalian host cell transformed with a structural gene encoding an HCV asialoglycoprotein selected from the group consisting of E1 and E2 in a suitable culture medium;

causing expression of said structural gene under conditions inhibiting sialylation; and

20 recovering said HCV asialoglycoprotein from said cell culture.

25 13. The method of claim 12, wherein said condition inhibiting sialylation comprises expression of E1 or E2 at a rate sufficient to inhibit transport of glycoproteins from the endoplasmic reticulum to the golgi.

14. The method of claim 12, wherein said conditions inhibiting sialylation comprise:

presence of a sufficient amount of a calcium modulator to cause release of proteins within the host cell's endoplasmic reticulum.

5 15. The method of claim 14, wherein said calcium modulator is thapsigargin.

16. A method for purifying hepatitis C virus (HCV) asialoglycoproteins, which method comprises:

10 contacting a composition containing HCV asialoglycoproteins with a mannose-binding protein; and
11 isolating the portion of the composition which binds to said mannose-binding protein.

12 17. The method of claim 16, wherein said mannose-binding protein is a lectin selected from the group consisting of ConA and GNA.

13 18. The method of claim 16, wherein said mannose-binding protein is immobilized on a support.

14 19. The method of claim 18, wherein:
15 said contacting comprises incubation of said composition containing HCV asialoglycoproteins in a column comprising a mannose-binding lectin immobilized on a support, for a period of at least one hour; and
16 said isolating comprises eluting said HCV asialoglycoproteins with
17 25 mannose.

18 20. An assay kit for detecting the presence of hepatitis C virus (HCV) asialoglycoproteins, said kit comprising:

Sub. B1

a solid support;
a mannose-binding protein; and
an antibody specific for said HCV asialoglycoprotein;
wherein one of said antibody and said mannose-binding protein is bound to
5 said solid support.

21. The assay kit of claim 20, wherein said mannose-binding protein is
GNA.

10 22. The assay kit of claim 20, wherein said antibody is bound to said
support and said mannose-binding protein is bound to a detectable label.

23. The assay kit of claim 20, wherein said mannose-binding protein is
bound to said support and said antibody is bound to a detectable label.

24. In a method for determining exposure to or infection by hepatitis C
virus (HCV), the method wherein any HCV within a sample of body fluid is concentrated
by contact with a mannose-binding protein prior to assay.

20 25. The method of claim 24, wherein said mannose-binding protein is
GNA.

26. A cell transformed with a vector for recombinant expression of a
hepatitis C virus (HCV) asialoglycoprotein, wherein said vector comprises a structural
25 gene encoding a glycosylation signal, an HCV asialoglycoprotein, a regulatory sequence
operable in said host cell and capable of regulating expression of said HCV asialoglyco-
protein, and a selectable marker; wherein said cell does not sialylate glycoproteins.

27. The cell of claim 26, wherein said cell is a glycosylation-defective yeast strain.

28. The cell of claim 26, wherein said vector comprises a vaccinia virus vector.

29. A method for reducing or eliminating the presence of hepatitis C virus (HCV) in plasma, serum, or other biological liquids which method comprises:
contacting said biological liquid with a mannose-binding protein specific for mannose-terminated glycoproteins; and
separating said biological liquid from said mannose-binding protein.

30. The method of claim 29 wherein said mannose-binding protein is GNA.

31. A method of inducing an immune response in an animal, which method comprises:
providing a vaccine composition comprising an effective amount of a hepatitis C virus (HCV) asialoglycoprotein in a pharmaceutically acceptable vehicle;
administering said vaccine composition to said animal.

32. The method of claim 31, wherein said HCV asialoglycoprotein is E1.

33. The method of claim 31, wherein said HCV asialoglycoprotein is E2.

34. The method of claim 31, wherein said HCV asialoglycoprotein is a purified E1/E2 aggregate.

35. The method of claim 31, wherein said animal is a primate.

36. A hepatitis C virus (HCV) asialoglycoprotein composition, comprising:
purified HCV E1/E2 asialoglycoprotein aggregate.

37. The composition of claim 36, wherein said HCV E1/E2 asialoglycoprotein aggregate is at least 40% pure.

38. The composition of claim 37, wherein said HCV E1/E2 asialoglycoprotein aggregate is at least 50% pure.

39. The composition of claim 38, wherein said HCV E1/E2 asialoglycoprotein aggregate is at least 60% pure.

40. The composition of claim 36, wherein said HCV E1/E2 asialoglycoprotein aggregate is substantially free of other HCV proteins.

41. The composition of claim 36, wherein said aggregate has a molecular weight of about 107 kD.

42. The composition of claim 36, wherein said aggregate has a molecular weight of about 800 kD.

add
A3

427212	427213	427214	427215	427216	427217	427218	427219	427220	427221	427222	427223	427224	427225	427226	427227	427228	427229	427230	427231	427232	427233	427234	427235	427236	427237	427238	427239	427240	427241	427242	427243	427244	427245	427246	427247	427248	427249	427250	427251	427252	427253	427254	427255	427256	427257	427258	427259	427260	427261	427262	427263	427264	427265	427266	427267	427268	427269	427270	427271	427272	427273	427274	427275	427276	427277	427278	427279	427280	427281	427282	427283	427284	427285	427286	427287	427288	427289	427290	427291	427292	427293	427294	427295	427296	427297	427298	427299	427300	427301	427302	427303	427304	427305	427306	427307	427308	427309	427310	427311	427312	427313	427314	427315	427316	427317	427318	427319	427320	427321	427322	427323	427324	427325	427326	427327	427328	427329	427330	427331	427332	427333	427334	427335	427336	427337	427338	427339	427340	427341	427342	427343	427344	427345	427346	427347	427348	427349	427350	427351	427352	427353	427354	427355	427356	427357	427358	427359	427360	427361	427362	427363	427364	427365	427366	427367	427368	427369	427370	427371	427372	427373	427374	427375	427376	427377	427378	427379	427380	427381	427382	427383	427384	427385	427386	427387	427388	427389	427390	427391	427392	427393	427394	427395	427396	427397	427398	427399	427400	427401	427402	427403	427404	427405	427406	427407	427408	427409	427410	427411	427412	427413	427414	427415	427416	427417	427418	427419	427420	427421	427422	427423	427424	427425	427426	427427	427428	427429	427430	427431	427432	427433	427434	427435	427436	427437	427438	427439	427440	427441	427442	427443	427444	427445	427446	427447	427448	427449	427450	427451	427452	427453	427454	427455	427456	427457	427458	427459	427460	427461	427462	427463	427464	427465	427466	427467	427468	427469	427470	427471	427472	427473	427474	427475	427476	427477	427478	427479	427480	427481	427482	427483	427484	427485	427486	427487	427488	427489	427490	427491	427492	427493	427494	427495	427496	427497	427498	427499	427500	427501	427502	427503	427504	427505	427506	427507	427508	427509	427510	427511	427512	427513	427514	427515	427516	427517	427518	427519	427520	427521	427522	427523	427524	427525	427526	427527	427528	427529	427530	427531	427532	427533	427534	427535	427536	427537	427538	427539	427540	427541	427542	427543	427544	427545	427546	427547	427548	427549	427550	427551	42755
--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------